Standard or custom package
excellent quality and reliable supplier
*The following content is generated by AI and is for reference only.
Overview
Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) primarily synthesized via pharmaceutical-grade organic synthesis. It functions by blocking VEGFR, FGFR, and RET pathways. The compound features the molecular formula C24H28ClFN4O3 and carries the CAS registry number 1220904-60-6.
Application
- Oncology: First-line treatment for advanced differentiated thyroid cancer.
- Hepatology: Combined therapy with pembrolizumab for unresectable hepatocellular carcinoma.
- Nephrology: Management of advanced renal cell carcinoma in specific patient cohorts.
Precautions
Strictly contraindicated during pregnancy due to embryofetal toxicity. Requires storage in a cool, dry place below 25°C under nitrogen protection. Healthcare personnel must utilize PPE to prevent dermal exposure and inhalation of dust particles.